Medicare plans can now cover Wegovy for patients at risk of heart disease

Date postedMarch 22, 2024
Industry,

For the first time, Medicare will allow coverage of one of the new blockbuster weight-loss drugs for enrollees in Part D plans.

The plans may now cover Wegovy when prescribed to prevent heart attacks and strokes, according to a new policy issued this week from the Centers for Medicare and Medicaid Services. Read more...

Categories

Community Women in PC Industry Patient Care and Advocacy

Most Recent Posts

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with FCS Date postedDecember 19, 2024Posted Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial Date postedDecember 4, 2024Posted AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE Date postedNovember 26, 2024Posted Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA Date postedNovember 22, 2024Posted Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes Date postedNovember 18, 2024Posted